IceCure Medical received approval from the Institutional Review Board at West Cancer Center to start a post-marketing study called the ChoICE Study for its ProSense® cryoablation device, used in treating low-risk breast cancer in women aged 70 and above. ProSense® is FDA-approved as a minimally invasive alternative to surgery, showing low recurrence rates and high patient satisfaction. The study will enroll 400 patients across 30 sites to gather real-world data and expand access to this treatment. This marks a significant step in advancing non-surgical cancer care options for elderly patients.
Berkshire Hathaway has allocated 29.7% of its $356 billion investment portfolio to just two artificial intelligence stocks. This significant concentration underscores the growing confidence and interest in AI technologies as key drivers of future gro...
Applied Materials shares have dropped about 32% from their all-time highs amid concerns over the semiconductor equipment cycle and high-profile short selling by investor Michael Burry. Despite the recent steep correction, the company benefits from st...
SK Hynix reported a 257% year-over-year revenue increase in Q2 2026, fueled by strong demand for AI-related DRAM and NAND memory products. The company benefits from a leading position in the high-bandwidth memory market and maintains robust financial...
Bitcoin transfer volume among retail investors making transactions under $10,000 increased by 9.36% over the past 30 days, reversing a steep decline seen earlier in 2026. This rise comes during a period of stable Bitcoin prices around $64,000 to $65,...
Agios Pharmaceuticals saw mitapivat revenue jump 259% year-over-year to $44.7 million in Q2 2026, driven by the launch for thalassemia treatment. The company is leveraging mitapivat's platform across rare diseases like PK deficiency, thalassemia, and...
